Sanofi has committed an additional $625m to its venture capital arm, Sanofi Ventures, bringing its total assets under management to more than $1.4bn. 

The move aims to bolster investments in biotech and digital health innovations, aligning with Sanofi's strategic focus on immunology, neurology, vaccines and rare diseases. 

Established in 2012, Sanofi Ventures has invested $800m in more than 70 companies, targeting early-stage and emerging opportunities in healthcare. 

The fund participates in various stages of the private company lifecycle, including seed funding, crossover investments and initial public offerings. 

It also holds board positions to support its portfolio companies. 

Sanofi CEO Paul Hudson stated: “This new, significant capital commitment reflects our strong belief that some of the most important medical breakthroughs begin in early-stage companies. 

“With a proven track record of strategic wins and successful exits, Sanofi Ventures has become a powerful engine for scientific progress and strategic growth. 

“By strengthening our investment capabilities, we are accelerating our ability to bring next-generation therapies that improve people’s lives while building valuable partnerships across the healthcare ecosystem.” 

The increased funding commitment comes as early-stage investment opportunities in the biotech sector are becoming scarce. 

It positions Sanofi Ventures to play a key role in nurturing healthcare innovations. 

The fund provides startups with financial resources and strategic guidance, assisting them in advancing therapies through critical development phases. 

This initiative supports Sanofi's future innovation pipeline and reinforces the company's influence in healthcare advancements. 

In July 2025, Sanofi agreed to acquire Vicebio, a UK-based biotechnology company, for $1.15bn upfront, and additional milestone payments up to $450m. 

The acquisition is expected to expand its vaccine development capabilities.